ALYSSA BALLANTYNE: Open Payments
NPI 1730918905 · ALBANY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,516 in 67 payments from 23 companies in 2025. Trend: 2023 $0 · 2024 $243 · 2025 $1,516
Food & beverage: $1,516
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 6 | $320 |
| ABBVIE INC. | 13 | $290 |
| Lilly USA, LLC | 9 | $168 |
| Phathom Pharmaceuticals, Inc. | 8 | $130 |
| Novo Nordisk Inc | 5 | $106 |
| GlaxoSmithKline, LLC. | 4 | $65 |
| Otsuka America Pharmaceutical, Inc. | 2 | $43 |
| Seqirus USA Inc | 1 | $36 |
| Edwards Lifesciences Corporation | 1 | $36 |
| Optinose US, Inc. | 2 | $35 |
Products named: BREZTRI, VRAYLAR, QULIPTA, VOQUEZNA, MOUNJARO, FARXIGA, JARDIANCE, REXULTI.
Industry payments across NY — which companies pay providers there.
